Background Artemisinin-resistant falciparum malaria has arisen in western Cambodia. A concerted international eff ort is underway to contain artemisinin-resistant Plasmodium falciparum, but containment strategies are dependent on whether resistance has emerged elsewhere. We aimed to establish whether artemisinin resistance has spread or emerged on the Thailand-Myanmar (Burma) border.
Introduction
Artemisinin combination treatments are the recommended fi rst-line therapy for falciparum malaria. Plasmodium falciparum parasites with reduced in-vivo susceptibility to artemisinin derivatives (eg, artesunate) have emerged in western Cambodia. [1] [2] [3] This fi nding threatens worldwide initiatives to control and eliminate malaria. 4 Resistance to the previous mainstays of antimalarial treatment-namely, chloroquine and sulfadoxinepyrimethamine-also arose in western Cambodia [5] [6] [7] and spread across southeast Asia into Africa, resulting in the deaths of millions of children. 8, 9 If resistance to artemisinin is confi ned to the Cambodia-Thailand border, regional elimination of falciparum malaria will probably be necessary for containment. 10, 11 However, if resistant parasites have already spread or emerged elsewhere, then the containment zone will need to be extended and the strategy reconsidered. 3, 7 Artemisinin resistance is characterised by slow parasite clearance. 1, 2, 12 Clearance (assessed by microscopy) of sensitive P falciparum is achieved within 2 days in 95% of patients, 13 whereas artemisinin-resistant infections remain slide-positive for 3 or more days; treatment failure is more common in such infections after arte misinin combination treatment. High-grade artemisinin resistance has not been reported. Laboratory studies and mathematical modelling suggest that slow clearance of resistant parasites mainly results from decreased susceptibility of ring-stage parasites to artemisinin and its derivatives. 14 No laboratory assays reliably identify artemisinin-resistant parasites. 2 Patients from western Cambodia with similar parasite clearance rates are infected with genetically in dis tin guishable parasite clones, suggesting that parasite genetics have a central role in determination of this trait, 15 although the genes responsible are unknown.
On the northwestern border of Thailand, 800 km from western Cambodia, treatment failure rates with artesunate and mefl oquine combinations have increased. 16 In this area, patients without signs of severity but with more than 4% parasitaemia (ie, parasites present in 4% or more of red blood cells) are given oral artesunate regimens, which have proven superior to intravenous quinine. 17, 18 High admission parasitaemias allow for accurate assessment of parasite clearance rates. To assess whether artemisinin resistance has emerged in this strategically important area, we analysed over 10 years the longitudinal changes in parasite clearance rates in a large prospective series of hyperparasitaemic patients given artesunate. Parasites were genotyped to establish the contribution of parasite genetics to parasite clearance rates.
Methods

Study site and patients
Data were obtained from patients with a high parasite count (>4% infected red blood cells) but no signs of severe malaria routinely admitted to malaria clinics run by the Shoklo Malaria Research Unit, which span a 150 km region of the northwestern border of Thailand. Maela (refugee camp) and Wang Pha village are north of Mae Sot town (where the research unit is based), whereas Mae Kon Khen and Mawker Thai villages are south (appendix). Most patients came from adjacent Myanmar (Burma). We compared the parasite clearance data with results from 119 patients studied in Pailin, western Cambodia (2007-10), where artemisinin resistance has been confi rmed. 2 A subset of 30 parasite genotypes from Pailin was part of the genetic analysis. These studies were approved by the ethics review boards of the Faculty of Tropical Medicine, Mahidol University.
Falciparum malaria was diagnosed by microscopy of thick and thin peripheral blood smears stained with Giemsa. Parasite counts were read per 1000 red cells (thin fi lm) or 500 white cells (thick fi lm). Uncomplicated hyper parasitaemia was defi ned as 4% or more of red cells infected with malaria parasites without clinical evidence of severe malaria, 19 and was the only criterion for inclusion in the analysis. Routine care was hospitalisation with a six hourly blood smear to monitor parasite clearance until smears were slide-negative. Treatment was with a 7 day regimen of oral artesunate (4 mg/kg initially, then 2 mg/kg once daily for 7 days), usually combined with either mefl oquine (25 mg/kg in two divided doses), or doxycycline (4 mg/kg per day for 7 days) or clindamycin (5 mg/kg three times daily for 7 days) if mefl oquine was contraindicated. In cases of clinical deterioration parenteral treatment was substituted. We monitored treatment until smears became slide-negative.
Procedures
DNA was extracted from admission blood spots by use of a two-step protocol to maximise DNA yield. Blood was eluted from six 3 mm diameter punches with the GenSolve kit (GenVault Corporation, Pleasanton, CA, USA), and DNA was then extracted with QIAamp 96 DNA blood kits (Qiagen, Valencia, CA, USA). Genotyping of 96 single nucleotide poly morphisms distributed across the P falciparum genome was done with the Illumina Goldengate platform (Illumina Inc, San Diego, CA, USA) (appendix). We judged samples to be multiple-clone infections if more than fi ve single nucleotide polymorphisms showed heterozygous base calls.
We measured the heritability of parasite clearance halflife to assess the part that parasite genetics plays in determination of this trait. Multilocus parasite genotypes infecting two or more patients were identifi ed. Such parasite genotypes are equivalent to identical twins reared apart and can be used to measure heritability of parasite clearance (panel 1).
The geometric mean parasite clearance half-life in patients with artemisinin-resistant falciparum malaria in western Cambodia was 6·2 h (n=36, 95% CI 5·7-6·6), 2, 15 corresponding to a log e normalised distri bution with a mean of 1·8 (SD 0·22 
Panel 1: Heritability
Measurement of heritability-ie, the proportion of variance in a trait that is explained by genetics-is widely used in human and agricultural genetics. 20 This measure is especially useful when the loci underlying trait variation are unknown and when the genetic and environmental contributions to trait variation are uncertain, as in the case of parasite clearance rates. Heritability can be measured in Plasmodium falciparum by comparing trait variation in genetically indistinguishable parasites infecting diff erent patients, just as heritability in people can be measured with identical twins. This approach uses the fact that such parasites are frequently recovered from several patients in southeast Asian countries because of low transmission and consequently high rates of inbreeding. 15 When resistance genes spread within a parasite population, heritability increases because genetic determinants have a growing role in determination of trait variation.
See Online for appendix reference artemisinin-sensitive population, with a mean log e parasite clearance half-life of 0·95 (0·33). The hypothesis that the changes in parasite clearance half-life in western Thailand resulted from emergence versus importation of parasites with the same resistance pheno type prevalent in western Cambodia was tested.
Statistical analysis
We assessed parasite clearance using a standardised fi tting method that separates the variable initial lag phase, during which parasite counts level off or rise, from the subsequent log-linear decline. 12 The slope of this phase was calculated and expressed as the parasite clearance half-life, which is the time taken for parasitaemia to fall by half during loglinear decline. 21 Patients with parasite clearance curves showing a poor fi t (R²<0·8) to the log-linear model were excluded from the analysis. We used Stata (version 11) to examine the association between parasite clearance half-life and the following covariates: age, sex, history of malaria, treatment regimen (artesunate with mefl oquine vs artesunate with other partner drugs or artesunate alone), date of admission, dura tion of fever before presentation (<3 days vs ≥3 days), admission parasitaemia, haematocrit (<30% vs ≥30%), gameto cytaemia, blood transfusion, and parenteral rescue therapy.
Univariate regression analysis of all listed covariates was done on log-transformed parasite clearance half-lives, followed by stepwise multivariate analysis (exclud ing parenteral rescue therapy). Variables that only signifi cantly improved the fi nal model (likelihood ratio test p<0·05) were included (tables 1, 2).
To assess heritability, variance of parasite clearance was compared within and between clonally identical parasites recovered from more than two patients. Heritability (H²) was estimated from the mean squares terms in ANOVA. 15, 21 H² was estimated for normalised parasite clearance and for residuals remaining after regression of clearance rates against patient and environmental factors.
We examined the hypothesis that changes in parasite clearance resulted from importation or emergence of parasites with the western Cambodian phenotype. The clearance rate distribution of a mixture of the western Cambodia and western Thailand populations was calculated as: π × normal([log{x} -1·8] / 0·22) + (1 -π) × normal([log{x} -0·95] / 0·33), where π is the proportion of infections derived from the resistant population. For each year, we used the Kolmogorov-Smirnov test (50 tests for each year) to compare recorded distributions of log e transformed half-lives with these theoretical distributions (for π between 0·01 and 0·50).
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and fi nal responsibility for the decision to submit for publication. 18 Between 2001 and 2010, the median age of hyperparasitaemic patients increased slightly but signifi cantly from 11 years to 15 years (p<0·0001). The proportion of patients developing severe malaria did not increase over time, nor did the ratio of severe to uncomplicated falciparum malaria cases, malaria mortality, nor the proportion of patients developing anaemia. We noted a signifi cant increase in the proportion of patients with gametocytaemia on admission (p<0·0001; 7·5×10 -⁶ test for trend).
Parasite clearance half-life lengthened from a geometric mean of 2·6 h (95% CI 2·5-2·7) in 2001, to 3·7 h (3·6-3·8) in 2010 (p<0·0001), compared with 5·5 h (5·2-5·9) in the 116 patients from western Cambodia between 2007 and 2010 (clearance data from three patients fi tted poorly to the linear model [R²<0·8] and were thus excluded) (fi gures 1, 2A, table 1). We used a stringent threshold of a parasite clearance half-life of more than 6·2 h to cate gorise infections with slow or fast parasite clearance; the proportion of patients at our study centres with slow clearance rose from 0·6% in 2001, to 20% in 2010, compared with 42% of patients in western Cambodia in 2010 (fi gure 2B). Parasite clearance rates in patients given artesunate monotherapy or given artesunate alone for more than 48 h (n=1759) before receiving partner drugs were similar to those in patients who were given combination treatments immediately, suggesting that increasing resistance to the partner drug cannot explain the temporal changes reported.
No relation existed between parasite clearance half-life and age (p=0·439) or starting parasitaemia (p=0·598) in patients given artesunate monotherapy or given artesunate alone for more than 48 h before receiving partner drugs, nor in all patients (p=0·124 and p=0·569, respectively). The variable most strongly associated with increases in parasite clearance half-life was the date of patient admission (appendix). This trend was strongly signifi cant in all clinics sampled except Mae Khon Ken, Thailand (table 2; After adjustment for the eff ects of covariates, H² rose from 0·32 (0·14) between 2001-04, to 0·58 (0·05) in 2007-10 (appendix). The increase in H² was tested by permutation and was signifi cant both before (p<0·01) and after (p=0·04) adjustment for covariates (appendix).
To investigate whether the increase in H² was driven by alleles conferring slow parasite clearance, we removed 30% of the slowest clearing infections from the 2007-10 dataset, which caused H² to decrease from 0·66 (SD 0·04) to 0·17 (0·07). Removal of 30% of the fastest clearing infections increased H² to 0·70 (0·05), whereas random removal of 30% of infections did not alter H² (mean H² from 100 randomisations 0·67 (0·03); range 0·56-0·74). These in-silico experiments show that high H² is driven by parasite genes that determine slow parasite clearance.
Admixture of parasites with the Cambodian phenotype could explain the parasite clearance distributions in 2001-02, and 2009-10, but not those between 2003 and 2008 (p<0·01). This fi nding suggests that the gradual increases in parasite clearance half-life are unlikely to be explained by a single-step process of importation or denovo selection of a parasite population with the same characteristics as the resistant parasites prevalent in western Cambodia.
None of the 93-locus genotypes was common to patients from the Thailand-Myanmar border and western Cambodia. Pairwise allele sharing (ps) between the 25 slowest and 25 fastest clearing parasites from the Thailand-Myanmar border was compared with 30 slowclearing parasites from western Cambodia. Cambodian parasites were more closely related (ps=0·453) to slowclearing parasites than to fast-clearing parasites (ps=0·450) from the Thailand-Myanmar border. However, permutation tests show that this diff erence is not signifi cant (p=0·137, 10 000 permutations).
Discussion
This large prospective series of patients with hyperparasitaemia during 10 years provides clear evidence that parasite clearance responses after artesunate treatment are slowing on the northwestern border of Thailand (panel 2). The rate of decline is consistent with theoretical expectations and empirical data for the spread of resistance loci through a parasite population under drug selection. [27] [28] [29] If the rate of decline continues then parasite clearance halflives on the Thailand-Myanmar border will be similar to those in western Cambodia within 2-6 years.
Parasite clearance after treatment with artemisinin derivatives is determined mainly by drug eff ectiveness, although host immunity and the partner drug can also contribute. 12 The frequency of malaria and the proportion of multiple-clone infections (appendix) in the study area in northwestern Thailand have fallen over the past 10 years; thus immunity to malaria has probably also declined. Because patients with hyperparasitaemia are unable to control their infection, changes in immunity are unlikely to have contributed substantially to the slowing of parasite clearance. The absence of any relation with age in this study provides strong support for this contention.
Similarly, although previous malaria exposure has a weak eff ect on parasite clearance half-life (table 1) , this fi nding cannot explain the temporal trends noted (appendix). The artemisinin combination treatment partner drug mefl oquine has been used in this region for more than 25 years, and resistance developed rapidly after initial deploy ment. The proportion of P falciparum isolates with increased pfmdr1 copy numbers (the main determinant of mefl oquine resistance) has been increasing over the past decade. 16 However, the temporal changes in parasite clearance half-lives for patients given artesunate monotherapy for more than 48 h before administration of partner drugs were closely related to those reported in the full dataset, showing that resistance to the partner drug does not contribute substantially to the changes recorded (fi gure 2). The genotyping data provide compelling evidence that parasite genetic factors explain the fall in parasite clearance rates. In this low transmission setting, diff erent patients are often infected with genetically very similar parasites, allowing assessment of the contribution of genetic factors to in-vivo phenotypes. 15, 30 After adjustment for covariates, the heritability of parasite clearance increased during the study period, from 32% between 2001 and 2004, to 58% between 2007 and 2010, which is consistent with an increasing prevalence of alleles determining slow parasite clearance. 20 The increased contribution of genetics was confi ned largely to the parasites with the slowest clearance rates. The high heritability of slow parasite clearance suggests that this trait will spread rapidly under continued selection.
This study shows the importance of longitudinal detailed monitoring to detect the early emergence of antimalarial drug resistance. Hyperparasitaemic patients provide important information on temporal trends in artemisinin susceptibility because confounding by immunity and partner drug eff ects is minimised and clearance rates can be assessed accurately (>10 sequential parasite counts for individual patients in this analysis). The slope, and thus the derived parasite clearance half-life of the exponential decline (ignoring the variable lag phase) is judged the key pharmacodynamic determinant of the artemisinins. 21 No evidence suggests saturation or density dependence in parasite clearance rates. Thus parasite clearances in patients with hyperparasitaemia can be compared with data from patients with lower parasitaemias, notably the artemisininresistant P falciparum infections in western Cambodia.
This study cannot establish whether resistance alleles present in western Cambodia and northwestern Thailand have a common origin. Parasites with identical 93-locus genotypes were not recorded at the two sites, nor were slow clearing parasites from northwestern Thailand more closely related to Cambodian parasites than were fast clearing parasites from western Thailand. The evolution of artemisinin resistance will possibly be understood when the genetic determinants of parasite clearance rates have been identifi ed. 7, 31 Parasite clearance rates in northwestern Thailand are continuously distributed. Modelling of the changes in parasite clearance over time did not support selection of a single artemisinin-resistant subpopulation with the same clearance phenotype as in Cambodia-ie, a one-step process. Together with the fi nding that clonally identical parasites with slow parasite clearance were reported in diff erent patients in northwestern Thailand 8 years ago, this result argues against recent importation of Cambodian parasites as the explanation for the reduction in parasite clearance.
The artesunate-mefl oquine combination has been the fi rst-line treatment for falciparum malaria on the western border of Thailand since 1994. Artesunate was added to a failing mefl oquine regimen, and the high eff ectiveness of the combination (>90% day 42 cure rates) has been sustained since then, although evidence suggests that eff ectiveness is decreasing, 16 with a day 42 cure rate in 86 patients in 2010 of 88·9% (95% CI 77·8-94·7). Declining artemisinin eff ective ness will have an adverse eff ect on the treatment of uncomplicated falciparum malaria by slowing therapeutic responses and increasing treatment failure rates, and will reduce the remarkable life-saving eff ectiveness of artesunate in the treatment of severe malaria and hyperparasitaemic patients. The degree to which current rates of resistance compromise these benefi ts has not been established, although the proportion of patients developing severe malaria did not increase concomitantly with the decline in artesunate eff ectiveness in this location. No patient died in this series, whereas in the past the mortality rate in patients given quinine for uncomplicated hyperparasitaemia was 3%.
A potential radical approach to containment of artemisinin resistance is to try to eliminate P falciparum malaria from western Cambodia, but would this strategy be justifi ed if resistance has already spread or emerged 
Systematic review
We searched for trials on artemisinin resistance on PubMed using the term "resistance" in combination with "artemisinin", "artesunate", or "artemether", and confi ned the search to clinical studies in which resistance had been suspected or confi rmed on the basis of assessment of parasite clearance. Additionally, we searched for all clinical trials or assessments of artemisinin combination treatments. We identifi ed 101 references. The only area where slow parasite clearance has been unambiguously shown previously is western Cambodia (four studies reporting parasite clearance). 1, 2, [22] [23] [24] Artemisinin resistance has been suspected because of diminishing treatment responses to artemisinin combination therapies on the western border of Thailand 16, 25 and changes in parasite clearance rates on the Kenyan coast. 26
Interpretation
Although artemisinin resistance has been suspected outside western Cambodia, this study provides the fi rst unequivocal proof that resistance has emerged or spread westward. It confi rms (with a large sample size) fi ndings showing that this phenotype is explained mainly by a heritable genetic trait in the parasite population. The research suggests a potential transmission advantage associated with resistance to artesunate through increased gametocyte carriage on admission. These fi ndings suggest that regional artemisinin resistance-containment strategies should be reviewed. Increasing the availability of artemisinin combination therapies in southeast Asia will reduce the incidence of malaria but provides a selection pressure driving artemisinin resistance. The development of strategies to reduce the selection and spread of artemisinin-resistant Plasmodium falciparum while continuing to drive down the incidence of malaria is of the highest priority. elsewhere? 7 Genetically determined resistance to artemisinins is now prevalent on the Thailand-Myanmar border, contiguous with a malaria endemic area in which a large burden of uncontrolled disease exists, so containment eff orts will need to be expanded and surveillance and control strategies re-examined. Whether the fi tness and transmissibility of the resistant parasites in the two locations are similar cannot be established yet, and thus elimination of falciparum malaria in western Cambodia might still be benefi cial through prevention of the spread of higher degrees of resistance.
Identifi cation of a molecular marker will be crucial to monitor the distribution and spread of resistance and to understand the evolution of this trait and the mechanism of action of artemisinin. The large numbers of patients infected with malaria, high heritability, and the broad range of parasite clearance half-lives make the Thailand-Myanmar border region ideal for powerful association studies. 32 Clinical studies are needed urgently to map further spread and to establish the eff ect of diff erent degrees of artemisinin resistance on treatment eff ectiveness and transmissibility.
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